Abstract
Objective
To examine the effect of carbamazepine on the single oral dose pharmacokinetics of etizolam.
Methods
Eleven healthy male volunteers received carbamazepine 200 mg/day or placebo for 6 days in a double-blind, randomized, crossover manner, and on the sixth day they received a single oral 1-mg dose of etizolam. Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 24 h after etizolam dosing. Plasma concentration of etizolam was measured using high-performance liquid chromatography.
Results
Carbamazepine treatment significantly decreased the peak plasma concentration (17.5±4.1 ng/ml versus 13.9±4.1 ng/ml; P<0.05), total area under the plasma concentration–time curve (194.8±88.9 ng h/ml versus 105.9±33.0 ng h/ml; P<0.001), and elimination half-life (11.1±4.6 h versus 6.8±2.8 h; P<0.01) of etizolam. No significant change was induced by carbamazepine in the two pharmacodynamic parameters.
Conclusions
The present study suggests that carbamazepine induces the metabolism of etizolam.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The thienodiazepine etizolam shows pharmacological effects similar to those of diazepam [21]. Etizolam is used in the treatment of psychiatric disorders such as general anxiety disorder [6] and panic disorder [17]. Unpublished data from the manufacturer (Mitsubishi Pharma 2003, unpublished data in package insert) suggest that etizolam is metabolized mainly by hydroxylation of the methyl group (1′-hydroxylation) and that of the ethyl group.
Cytochrome P450 (CYP) 3A4 is the major enzyme catalyzing the metabolism of several benzodiazepines, e.g., alprazolam [25, 26], brotizolam [20], midazolam [14], and triazolam [22]. This enzyme is also partly involved in the metabolism of diazepam [1, 13], flunitrazepam [13], and quazepam [12]. Unpublished in vitro data suggest that CYP3A4 catalyzes the 1′-hydroxylation of etizolam (Mitsubishi Pharma 2003, unpublished data in package insert). Our recent study suggests that itraconazole, an inhibitor of CYP3A4, inhibits the metabolism of etizolam in humans, providing in vivo evidence that CYP3A4 is at least partly involved in etizolam metabolism [3].
It has been shown that carbamazepine induces CYP3A4 activity [16, 24, 27]. In fact, carbamazepine induces the metabolism of alprazolam [8] and midazolam [4]. Therefore, it is expected that carbamazepine induces the metabolism of etizolam as well.
To clarify this point, the authors examined the effect of carbamazepine on the single oral dose pharmacokinetics of etizolam.
Subjects and methods
The subjects were 11 healthy male volunteers. They were all Japanese. The mean±SD age was 33±9 years, and that of body weight was 73±13 kg. No subject had taken any drug or food that affects CYP3A4 activity for at least 1 week before the study. The study protocol was approved by the ethics committees of Yamagata University School of Medicine and Hirosaki University School of Medicine, and each subject gave his written informed consent before the study.
The study was conducted in a double-blind, randomized, crossover manner, with at least a 4-week washout period. The subjects were randomly allocated to one of the two treatment sequences: placebo-carbamazepine or carbamazepine-placebo. Carbamazepine 200 mg as the tablet formulation (Tegretol, Novartis Pharma, Tokyo, Japan) or matched placebo was given orally at 2100 hours for 6 days. After an overnight fast, at 0900 hours of the 6th day, a single oral 1-mg dose of etizolam (Depas, Mitsubishi Pharma, Osaka, Japan) as the tablet formulation was given with a cup of tap water. No food was allowed until 3 h after etizolam dosing. Blood samples (10 ml each) for etizolam measurement were taken before and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after etizolam dosing. Blood samples for carbamazepine measurement were taken at 0900 hours on the 6th day. At times of blood samplings, psychomotor function was assessed using the digit symbol substitution test (DSST) adapted from the Wechsler Adult Intelligence Scale [23] in 90 s, and the Stanford Sleepiness Scale (SSS) [11].
Plasma concentration of etizolam was measured by means of the high-performance liquid chromatography (HPLC) method of Hikida et al. [10]. The lowest limit of detection [signal/noise ratio (S/N)=3] was 0.3 ng/ml, and that of quantification (S/N=6) was 0.6 ng/ml. The coefficients of variation (CV) at the concentrations of 1, 5, and 20 ng/ml were all less than 2.8%. Plasma concentration of carbamazepine was measured using the same HPLC method as for etizolam with some modifications. The lowest limit of detection was 0.05 μg/ml, and that of quantification was 0.1 μg/ml. The CV at the concentrations of 0.5, 2.5, and 5.0 μg/ml were all less than 0.8%.
The elimination rate constant (k) was estimated by the linear regression analysis of the terminal log-linear plasma concentration–time curve. The elimination half-life (t1/2) was calculated by 0.693/k. The area under the plasma concentration–time curve (AUC) from 0 h to 24 h [AUC(0–24)] was calculated using the trapezoidal rule. The AUC from 0 h to infinity [AUC(0–∞)], or total AUC, was calculated by AUC(0–24)+C24/k, in which C24 is the plasma concentration at 24 h. The peak plasma concentration (Cmax) and time to Cmax (tmax) were determined graphically. For the DSST and SSS, the area under the score-time curve from 0 h to 24 h [AUSC(0–24)] was calculated.
The paired t test was used to examine whether there were significant differences between the placebo and carbamazepine phases in the mean plasma concentrations, and in pharmacokinetic and pharmacodynamic parameters of etizolam. A P value of 0.05 or less was considered statistically significant. In the bioequivalence statistics, the 90% confidence interval (CI) of the carbamazepine/placebo ratio of each parameter was calculated and compared with the bioequivalence range of 0.80–1.25 [18].
Results
During the placebo phase, plasma etizolam concentrations were measurable for up to 24 h in all subjects. However, during the carbamazepine phase, plasma etizolam concentrations were no longer measurable at 24 h in four subjects. Carbamazepine treatment significantly (P<0.05–0.001) decreased plasma etizolam concentrations at all time points except at 0.25 h (Fig. 1).
Carbamazepine significantly decreased the Cmax (P<0.05), total AUC (P<0.001), and elimination t1/2 (P<0.01) of etizolam (Table 1). The greatest individual decreases in these parameters were 39, 59, and 76%, respectively, which were observed in three separate subjects. The 90% CIs of the carbamazepine/placebo ratio of the total AUC and elimination t1/2 were not contained in the bioequivalence range of 0.80–1.25.
The AUSC (0–24) of DSST and SSS were not significantly different between the two phases (Table 1). The mean (±SD) plasma concentration of carbamazepine at 0900 hours was 4.3±1.5 μg/ml.
Discussion
In the present study, the number of subjects was not decided beforehand by a power calculation. However, a post-hoc power calculation revealed that the actual number of subjects (n=11) was sufficient to detect even a small change caused by carbamazepine. For instance, the power to detect a change of 19.5 ng h/ml in the total AUC (10% of the mean value of the placebo phase) at the significance level of 0.05 was calculated as 0.89 [28].
Alprazolam [25, 26] and midazolam [14] are representative substrates of CYP3A4. Furukori et al. [8] have shown that carbamazepine treatment markedly decreased the total AUC and elimination t1/2 of alprazolam in healthy volunteers. Backman et al. [4] have reported that the Cmax, total AUC, and elimination t1/2 of midazolam were markedly decreased in epileptic patients taking carbamazepine in comparison with healthy volunteers. These studies indicating that carbamazepine induces the metabolism of CYP3A4 substrates prompted us to examine the effect of carbamazepine on etizolam metabolism.
The results of this study were largely in line with those of the studies on alprazolam and midazolam. Carbamazepine treatment significantly decreased plasma etizolam concentrations at almost all time points. As to the pharmacokinetic parameters, carbamazepine significantly decreased the Cmax, total AUC, and elimination t1/2 of etizolam. The bioequivalence statistics showed significant effects of carbamazepine on the total AUC and elimination t1/2 of etizolam. These results strongly suggest that carbamazepine induces the metabolism of etizolam. This metabolic induction may be mediated by CYP3A4, although other CYP enzyme(s) may also be involved. For instance, it has been reported that CYP1A2 is also inducible by carbamazepine [15].
To take the decrease in total AUC as an index of metabolic induction by carbamazepine, the value of etizolam (42%) was smaller than that of alprazolam (58%) [8] and much smaller than that of midazolam (94%) [4]. This relative extent may be partly explained by the differences in doses of carbamazepine (200 mg versus 300 mg versus 700–900 mg/day) and duration of treatment (6 days versus 8 days versus at least 2 months).
As mentioned above, carbamazepine decreased plasma etizolam concentrations, but this was not accompanied by significant changes in the pharmacodynamic parameters. The possibility that this negative result is ascribable to the sedative effect of carbamazepine itself [2] cannot be excluded, though the baseline scores of the DSST and SSS were not significantly different between the placebo and carbamazepine phases (data not shown). Another possibility is that the formation of 1′-hydroxyetizolam, which is suggested to be equipotent to the parent compound [7], was increased in the carbamazepine phase, and increased sedation by this active metabolite nullified the pharmacodynamic consequence of decreased etizolam.
In the present study, carbamazepine treatment of a rather short period of 6 days was used for an ethical reason. It has been suggested that the enzyme-inducing effect of carbamazepine is maximal at 3–5 weeks [5]. Therefore, the possibility that carbamazepine treatment over a longer period than in this study further induces etizolam metabolism, leading to significant pharmacodynamic changes, remains.
The elimination t1/2 of etizolam in this study (11.1 h) was much longer than that in one study conducted in Caucasians (3.4 h) [7]. This difference does not appear to be explained by CYP3A4 activity, since another study has suggested that there is no clear difference in CYP3A4 activity between Japanese and Caucasians [19]. Other CYP enzyme(s), showing clear interethnic differences, e.g., CYP2C19 [9], may be involved in the difference in elimination t1/2 mentioned above.
In conclusion, the present study suggests that carbamazepine induces the metabolism of etizolam.
References
Ahonen J, Olkkola KT, Neuvonen PJ (1996) The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 10:314–318
Albani F, Riva R, Baruzzi A (1995) Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 28:235–244
Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427–430
Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253–257
Bertilsson L, Tomson T (1986) Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 11:177–198
Casacchia M, Bolino F, Ecari U (1990) Etizolam in the treatment of generalized anxiety disorder: a double-bind study versus placebo. Curr Med Res Opi 12:215–223
Fracasso C, Confalonieri S, Garattini S, Caccia S (1991) Single and multiple dose pharmacokinetics of etizolam in healthy subjects. Eur J Clin Pharmacol 40:181–185
Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Neuropsychopharmacology 18:364–369
Goldstein JA, de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285–299
Hikida K, Inoue Y, Nouchi E, Ohkura Y (1990) Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography. Jpn J Clin Chem 19:354–359
Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: a new approach. Psychophysiology 10:431–436
Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K (2003) Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Ther Drug Monit 25:473–477
Luurila H, Olkkola KT, Neuvennen PJ (1996) Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 78:117–122
Olkkola KT, Beckman JT, Neuvenen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–485
Parker AC, Pritchard P, Preston T, Choonara I (1998) Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 45:176–178
Pirmohamed M, Allott R, Green VJ, Kitteringham NR, Chadwick D, Park BK (1994) Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol 37:577–581
Savoldi F, Somenzini G, Ecari U (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opi 12:185–190
Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29:323–328
Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR (2001) CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 69:333–339
Tokairin T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2004) Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol (in press)
Tsumagari T, Nakajima A, Fukuda T, Shuto S, Kenjo T, Morimoto Y, Takigawa Y (1978) Pharmacological properties of 6-(o-chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo[3,4-c]thieno[2,3-e][1,4]diazepine(Y-7131), a new anti-anxiety drug. Arzneimittelforschung 28:1158–1178
Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 56:601–607
Wechsler D (1981) Wechsler adult intelligence scale-revised. Harcourt Brace Jovanovich, New York
Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S (1989) Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 36:401–406
Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514–519
Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269–273
Yue QY, Tomson T, Sawe J (1994) Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 4:193–198
Zar JH (1996) Biostatistical analysis. Upper saddle river, 3rd edn. Prentice-Hall, NJ
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kondo, S., Fukasawa, T., Yasui-Furukori, N. et al. Induction of the metabolism of etizolam by carbamazepine in humans. Eur J Clin Pharmacol 61, 185–188 (2005). https://doi.org/10.1007/s00228-005-0904-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0904-y